Saltar al contenido
Merck

Striatal dopamine receptor plasticity in neurotensin deficient mice.

Behavioural brain research (2014-12-03)
Lucy G Chastain, Hongyan Qu, Chase H Bourke, P Michael Iuvone, Paul R Dobner, Charles B Nemeroff, Becky Kinkead
RESUMEN

Schizophrenia is thought to be caused, at least in part, by dysfunction in striatal dopamine neurotransmission. Both clinical studies and animal research have implicated the dopamine neuromodulator neurotensin (NT) in the pathophysiology of schizophrenia. Utilizing male mice lacking the NT gene (NT(-/-)), these studies examined the consequences of NT deficiency on dopaminergic tone and function, investigating (1) dopamine concentrations and dopamine receptor and transporter expression and binding in dopaminergic terminal regions, and (2) the behavioral effects of selective dopamine receptor agonists on locomotion and sensorimotor gating in adult NT(-/-) mice compared to wildtype (NT(+/+)) mice. NT(-/-) mice did not differ from NT(+/+) mice in concentrations of dopamine or its metabolite DOPAC in any brain region examined. However, NT(-/-) mice showed significantly increased D1 receptor, D2 receptor, and dopamine transporter (DAT) mRNA in the caudate putamen compared to NT(+/+) controls. NT(-/-) mice also showed elevated D2 receptor binding densities in both the caudate putamen and nucleus accumbens shell compared to NT(+/+) mice. In addition, some of the behavioral effects of the D1-type receptor agonist SKF-82958 and the D2-type receptor agonist quinpirole on locomotion, startle amplitude, and prepulse inhibition were dose-dependently altered in NT(-/-) mice, showing altered D1-type and D2-type receptor sensitivity to stimulation by agonists in the absence of NT. The results indicate that NT deficiency alters striatal dopamine receptor expression, binding, and function. This suggests a critical role for the NT system in the maintenance of striatal DA system homeostasis and implicates NT deficiency in the etiology of dopamine-associated disorders such as schizophrenia.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Acetonitrilo, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Acetonitrilo, HPLC Plus, ≥99.9%
Sigma-Aldrich
Hidróxido de sodio, ACS reagent, ≥97.0%, pellets
Sigma-Aldrich
Hidróxido de sodio, reagent grade, ≥98%, pellets (anhydrous)
Sigma-Aldrich
Ácido fosfórico, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
Hidróxido de sodio solution, 50% in H2O
Sigma-Aldrich
Acetonitrilo, ACS reagent, ≥99.5%
Sigma-Aldrich
Acetonitrilo, anhydrous, 99.8%
Sigma-Aldrich
Ácido fosfórico, 85 wt. % in H2O, 99.99% trace metals basis
Sigma-Aldrich
Acetonitrilo, for HPLC, for UV, ≥99.9% (GC)
Sigma-Aldrich
Hidróxido de sodio solution, BioUltra, for molecular biology, 10 M in H2O
Sigma-Aldrich
Ácido fosfórico, ACS reagent, ≥85 wt. % in H2O
Sigma-Aldrich
Acetonitrilo, suitable for HPLC, gradient grade, ≥99.9%
Sigma-Aldrich
Hidróxido de sodio solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Ácido fosfórico, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥85%
Sigma-Aldrich
Hidróxido de sodio, BioXtra, ≥98% (acidimetric), pellets (anhydrous)
Sigma-Aldrich
Hydrobromic acid, ACS reagent, 48%
Sigma-Aldrich
Hidróxido de sodio, puriss. p.a., ACS reagent, reag. Ph. Eur., K ≤0.02%, ≥98%, pellets
Sigma-Aldrich
Hidróxido de sodio, reagent grade, 97%, powder
Sigma-Aldrich
Hidróxido de sodio, puriss., meets analytical specification of Ph. Eur., BP, NF, E524, 98-100.5%, pellets